title: Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: A
authors.initials: A
authors.lastname: Mele
authors.forename: M
authors.initials: M
authors.lastname: Malagola
authors.forename: A
authors.initials: A
authors.lastname: Isidori
authors.forename: C
authors.initials: C
authors.lastname: Finelli
authors.forename: P P
authors.initials: PP
authors.lastname: Piccaluga
mesh_terms: D001803:Blood Transfusion; D019468:Disease Management; D004351:Drug Resistance; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D004921:Erythropoietin; D013792:Thalidomide